文献速递乳腺乳腺X线USMR

多模态影像对新诊断乳腺癌的术前分期:对比增强能谱乳腺X线与常规乳腺X线、超声和MRI的诊断性能比较

Preoperative staging by multimodal imaging in newly diagnosed breast cancer: Diagnostic performance of contrast-enhanced spectral mammography compared to conventional mammography, ultrasound, and MRI.
PubMed 文献 · Eur J Radiol · 2023-04-15

该前瞻性单中心研究纳入128例新诊断乳腺癌患者,比较CESM与Mx、US、MRI的病灶检出率和术前局部分期。MRI检出率最高(100.0%),US(96.9%)和CESM(96.1%)次之,Mx最低(82.8%)(p=0.0002)。CESM对肿瘤范围的评估与MRI相当,优于Mx和US,且二次靶向超声检查率更低(10.2% vs 16.2%)而真阳性率更高(72.0% vs 42.5%)。

要点

  • CESM病灶检出率(96.1%)与US(96.9%)接近,显著高于常规Mx(82.8%)。
  • CESM评估肿瘤局部范围与MRI相当,优于Mx和US。
  • CESM引导二次超声检查的真阳性率高于MRI,减少不必要活检。

关键影像表现/征象

  • CESM和MRI对多灶性和多中心性病变的检出率最高(p<0.0001)。
  • 高乳腺密度对US、CESM或MRI的检出率无负面影响。

诊断标准与关键数值

  • 检出率:MRI 128/128(100.0%),US 124/128(96.9%),CESM 123/128(96.1%),Mx 106/128(82.8%)(p=0.0002)。
  • 局部肿瘤范围测量Bland-Altman偏倚:CESM 6.6(标准差30.2),Mx 23.4(标准差43.7),US 35.4(标准差40.5)。
  • 二次靶向超声检查率:CESM 10.2%,MRI 16.2%;真阳性率:CESM 72.0%,MRI 42.5%。

临床应用与阅片要点

  • CESM可作为MRI禁忌或不可用时的替代方案进行术前分期。
  • CESM评估肿瘤范围与MRI相当,可辅助手术方案制定。
  • CESM引导的二次超声检查真阳性率更高,有助于减少不必要的活检。

局限性

  • 单中心前瞻性观察性研究,样本量有限(128例)。
  • 未报告阅片者间一致性具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare contrast-enhanced spectral mammography (CESM) with mammography (Mx), ultrasound (US), and magnetic resonance imaging (MRI) regarding breast cancer detection rate and preoperative local staging.

MATERIAL AND METHODS: This prospective observational, single-centre study included 128 female patients (mean age 55.8 ± 11.5 years) with a newly diagnosed malignant breast tumour during routine US and Mx were prospectively enrolled. CESM and MRI examinations were performed within the study. Analysis included interreader agreement, tumour type and grade distribution, detection rates (DR), imaging morphology, contrast-enhancement and was performed by two independent readers blinded to patient history and histopathological diagnosis. Assessment of local disease extent was compared between modalities via Bland-Altman plots.

RESULTS: One-hundred-and-ten tumours were classified as NST (85.9%), 4 as ILC (3.1%) and 10 as DCIS (7.8%). DR was highest for MRI (128/128, 100.0%), followed by US (124/128, 96.9%) and CESM (123/128, 96.1%) and lowest for conventional Mx (106/128, 82.8%) (p = 0.0002). Higher breast density did not negatively affect DR of US, CESM or MRI. Local tumour extent measurements based on CESM (Bland-Altman bias 6.6, standard deviation 30.2) showed comparable estimation results to MRI, surpassing Mx (23.4/43.7) and US (35.4/40.5). Even though detection of multifocality and multicentricity was highest for CESM and MRI (p < 0.0001), second-look rates, i.e., targeted US examinations after MRI or CESM, were significantly lower for CESM (10.2% of cases) compared to MRI (16.2%) with a significantly higher true positive rate for CESM (72.0%) vs. MRI (42.5%).

CONCLUSION: CESM is a viable alternative to MRI for lesion detection and local staging in newly diagnosed malignant breast cancer and provides higher specificity in regard to second-look examinations.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Daniaux, Gruber, De Zordo, et al. Preoperative staging by multimodal imaging in newly diagnosed breast cancer: Diagnostic performance of contrast-enhanced spectral mammography compared to conventional mammography, ultrasound, and MRI. Eur J Radiol. 2023. PMID: 37080064. doi:10.1016/j.ejrad.2023.110838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。